Back

Zilebesiran in combination with a diuretic in patients with uncontrolled hypertension: a subgroup analysis from the Phase 2 KARDIA-3 trial

30 August 2026 (08:15 - 08:25)
Organised by: Logo
Congress Presentation Part of: Treatment of hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Neha Pagidipati

Duke Clinical Research Institute, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail
Heart failure and uncontrolled hypertension: recent evidence of routine care in Germany
Professor J. Weil (Luebeck, DE)
Abstract Slides
Presentation thumbnail
Effects of a novel low-dose triple combination on blood pressure variability: results from the TRIDENT trial
Doctor T. Wang (Sydney, AU)
Abstract Slides
Presentation thumbnail
Effects of intensive blood pressure control across the spectrum of renal impairment: a post hoc analysis from ESPRIT
Doctor S. Li (Beijing, CN)
Abstract Slides
Presentation thumbnail
Differences of the characteristics of uncontrolled versus controlled hypertensive patients, treated with at least three antihypertensive drugs: insights from the SNAPSHOT Europe study
Professor M. Camafort (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Efficacy and safety of potassium-enriched salt substitutes in hypertension management: a systematic review and meta-analysis
Mr T. Bonafe (Varzea Grande, BR)
Abstract Slides

Access the full session

Session thumbnail
Treatment of hypertension
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive
30 August 2024
thumbnail
Congress Presentation
Successful perindopril/amlodipine+indapamide treatment as second line in uncontrolled hypertensive patients in line with european guidelines
7 April 2022
thumbnail
Congress Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
27 August 2021
thumbnail
Congress Presentation
A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open label extension
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources